Table 2.
Classic NSCLC driver alterations in LCNEC and carcinoid.
| Patient ID | Gene | Alteration | Therapeutic evidencea | Subtype |
|---|---|---|---|---|
| L027 | EGFR | p.L858R | 1 | NSCLC-like LCNEC |
| L014 | EGFR | p.L858R | 1 | NSCLC-like LCNEC |
| KRAS | p.Q61L | 4 | ||
| L043 | EGFR | p.L858R | 1 | NSCLC-like LCNEC |
| EGFR | cn_amp | — | ||
| L017 | ERBB2 | cn_amp | 2 | NSCLC-like LCNEC |
| L041 | KRAS | p.G12C | 3A | NSCLC-like LCNEC |
| L003 | KRAS | p.G13C | 4 | NSCLC-like LCNEC |
| L052 | EGFR | cn_amp | — | NSCLC-like LCNEC |
| L054 | EGFR | cn_amp | — | NSCLC-like LCNEC |
| L002 | KRAS | cn_amp | — | NSCLC-like LCNEC |
| L016 | KRAS | cn_amp | — | NSCLC-like LCNEC |
| L031 | BRAF | p.D594G | — | NSCLC-like LCNEC |
| L051 | EGFR | p.L858R | 1 | SCLC-like LCNEC |
| EGFR | p.E709K | — | ||
| L013 | MET | cn_amp | 2 | SCLC-like LCNEC |
| L035 | MET | cn_amp | 2 | SCLC-like LCNEC |
| L012 | EGFR | cn_amp | 4 | SCLC-like LCNEC |
| C018 | ERBB2 | cn_amp | 2 | AC |
| C019 | ERBB2 | cn_amp | 2 | AC |
| C020 | ERBB2 | cn_amp | 2 | AC |
| C021 | ERBB2 | cn_amp | 2 | AC |
| KRAS | cn_amp | — | ||
| C024 | KRAS | cn_amp | — | AC |
Levels of evidence are adopted from OncoKB database: (1) FDA-recognized biomarker predictive of response to an FDA-approved drug in this indication; (2) standard care biomarker recommended by the NCCN or other expert panels predictive of response to an FDA-approved drug in this indication; (3A) compelling clinical evidence supports the biomarker as being predictive of response to a drug in this indication; (4) compelling biology evidence supports the biomarker as being predictive of response to a drug. AC: atypical carcinoid; LCNEC: large cell neuroendocrine carcinoma; SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer.